Jon Halbert - 17 Jun 2025 Form 3 Insider Report for Caris Life Sciences, Inc.

Reporting relationship: Director
Issuer ticker: CAI on Nasdaq
Reported as of: 17 Jun 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 17 Jun 2025, 21:30:09 UTC
Prior SEC filing: 23 Jun 2025
Next SEC filing: 27 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ J. Russel Denton, Attorney-in-Fact

Key filing fact

Jon Halbert filed Form 3 for Caris Life Sciences, Inc. on 17 Jun 2025.

Key facts

This page summarizes Jon Halbert's Form 3 filing for Caris Life Sciences, Inc..
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2025, 21:30.

Change

Previous filing in this sequence was filed on 23 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001189394 Primary reporting owner

HALBERT JON

Relationship: Director
Address: C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING
Signature: /s/ J. Russel Denton, Attorney-in-Fact
Signature date: 17 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 116,129
Date: 17 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CAI holding Derivative

Series A Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 17 Jun 2025
Ownership: By Ke'Ohana Ventures, LLC
Underlying class: Common Stock
Underlying amount: 1,250,000
Exercise price: $0.000000
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Includes 16,129 shares of Common Stock underlying restricted stock units which vest in accordance with the applicable grant agreement.

Footnote F2

Each share of preferred stock is convertible at the holder's option into 0.25 shares of Common Stock of the Issuer, subject to adjustment in accordance with the certificate of formation, and will automatically convert upon the closing of the initial public offering of the Issuer's Common Stock.

Footnote F3

The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

SEC remarks

Exhibit 24 - Power of Attorney.